

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/763,646	07/09/2001	Klaus Urich	VI/98-023.DE	7684
7590 05/24/2004			EXAMINER	
Gregory L Bradley			WILLIAMS, CATHERINE SERKE	
Medrad Inc One Medrad Dr	ive		ART UNIT	PAPER NUMBER
Indianola, PA		3763	21	
			DATE MAILED: 05/24/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

•		Application No.	Applicant(s)			
Office Action Summary		09/763,646	URICH, KLAUS			
		Examiner	Art Unit			
		Catherine S. Williams	3763			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
THE MAILING DATE OF THIS - Extensions of time may be available under after SIX (6) MONTHS from the mailing of the period for reply specified above is left. If NO period for reply is specified above, a Failure to reply within the set or extended.	COMMUNICATION. In the provisions of 37 CFR 1.13 ate of this communication. In the maximum statutory period we period for reply will, by statute, and three months after the mailing.	Y IS SET TO EXPIRE 3 MONTH(36(a). In no event, however, may a reply be time, within the statutory minimum of thirty (30) days, will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE of date of this communication, even if timely filed	nely filed s will be considered timely. the mailing date of this communication. O (35 U.S.C. § 133).			
	antian(a) filad an 00 AA	arch 2004				
1) Responsive to communic	* *					
<i>,</i> —						
	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
6)⊠ Claim(s) <u>17-25,27,32,33,</u> 7)⊠ Claim(s) <u>28-31,73-76,87.</u> 8)□ Claim(s) are subject the specification is object.	is/are withdray 37,46,49-66,91-99,10 62-70,72,77-84,86,10 90,109-111 and 113- ect to restriction and/o	wn from consideration. 1-103 and 132-137 is/are allowed 14-107,139,140,142 and 143 is/ar 131 is/are objected to. r election requirement.	e rejected.			
• • • • • • • • • • • • • • • • • • • •	☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
a) ⊠ All b) □ Some * c) □ 1. □ Certified copies of 2. □ Certified copies of 3. ⊠ Copies of the certi application from th	None of: the priority documents the priority documents fied copies of the priority e International Bureau	priority under 35 U.S.C. § 119(a) is have been received. In Application of the certified copies not received to the certified copies not received.	on No ed in this National Stage			
Attachment(s)	_		(DTO 110)			
 Notice of References Cited (PTO-89 Notice of Draftsperson's Patent Drav Information Disclosure Statement(s) Paper No(s)/Mail Date 	ring Review (PTO-948)	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:				

Continuation of Disposition of Claims: Claims pending in the application are 1,4-7,13,14,16-25,27-34,37,46,49-55,59,60,62-70,72-84,86-99,101-107,109-111,113-137,139,140,142 and 143.

Application/Control Number-09/763,646

Art Unit: 3763

DETAILED ACTION

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 17-25,27,32-33,62-70,72,77-84,86,104-107,139-140,142,143 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kranys et al (US Pat# 4,006,736) et al in view of Bernstein et al (US pat# 5,611,344). Kranys discloses an angiographic injector that includes an injector, a syringe a plunger and a movement mechanism (28). The injector and syringe have means cooperable for mounting. The movement mechanism is connected to the syringe. The movement mechanism is operable to move the syringe in a semi-circular (rotational) path. The fluid within the syringe is an ultrasound contrast agent. When the syringes are rotated it is considered inherent that any fluid contained therein will be agitated during the movement. The method steps are considered inherent for proper function of the device. For example, since a syringe, injector and movement mechanism are all disclosed it is inherent that they all must be provided. During use, once the syringes are rotated the claim language of "activating the movement mechanism" will be met. Once the syringes have complete a ½ turn it is inherent that the step of "deactivating the movement mechanism" has been met. See figures 2 and 3.

Kranys meets the claim limitations as described above but fails to include an agitation element that (i) has a density different from that of the fluid contained in the syringe, (ii) is a

Application/Control Number: 09/763,646

Art Unit: 3763

solid, (iii) is a gas and (iv) is surrounded by a cover. However, Bernstein discloses a microencapsulated fluorinated gas for use as an imaging agent. See summary of invention.

At the time of the invention, it would have been obvious to incorporate the imaging agent of Bernstein into the invention of Kranys. Bernstein discloses that this imaging agent has enhanced echogenicity compared with other agents. The motivation for the incorporation would have been in order to enhance the overall procedure of Kranys by using a known enhanced agent.

Allowable Subject Matter

Claims 1,4-7,14,16,34,37,46,49-66,91-99,101-103,132-137 are allowed.

Claims 28-31,73-76,87-90,109-111,113-131 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Catherine S. Williams whose telephone number is 703-308-4846.

The examiner can normally be reached on Monday - Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brian Casler can be reached on 703-308-3552. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 3763

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Catherine S. Williams May 17, 2004

BRIAN L. CASLER
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 3700